powerbatles The most interesting information in the quote is the initial date, which is as much as 9 years ago! This demonstrates the total failure of BDPT to capitalize on its products.
"LAS VEGAS, Dec. 7, 2014 /PRNewswire/ -- BioAdaptives, Inc. (BDPT) announced results of the recently completed in vivo trial showing the efficacy of its PrimiCell® product on muscle repair.
Percent Improvement with PrimiCell(R)
Percent Improvement with PrimiCell(R)
In the study mice were put into groups, PrimiCell® and the control group. The PrimiCell® group was given PrimiCell® for seven days prior to the treatment. Both groups were injected with cardiotoxin in the leg to cause muscle damage. At day one after the injection, day five, and day seven, test subjects from each group were analyzed to determine lesion size, inflammation, necrosis, and overall improvement. Results on day seven showed the PrimiCell® group had overall improvement greater than 56% better than the control group."
Market Data 
Markets 
AI
